Vanguard Information Technology ETF
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
148% more call options, than puts
Call options by funds: $659M | Put options by funds: $266M
10% more repeat investments, than reductions
Existing positions increased: 597 | Existing positions reduced: 544
0.97% less ownership
Funds ownership: 35.41% [Q4 2024] → 34.43% (-0.97%) [Q1 2025]
4% less funds holding
Funds holding: 1,703 [Q4 2024] → 1,630 (-73) [Q1 2025]
14% less capital invested
Capital invested by funds: $30.4B [Q4 2024] → $26B (-$4.4B) [Q1 2025]
18% less first-time investments, than exits
New positions opened: 102 | Existing positions closed: 125
21% less funds holding in top 10
Funds holding in top 10: 110 [Q4 2024] → 87 (-23) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for VGT.
Financial journalist opinion
Based on 14 articles about VGT published over the past 30 days
Positive
The Motley Fool
1 day ago
This Tech ETF Could Mint $500,000, or More
One of the best things to happen to stock investing is the introduction of exchange-traded funds (ETFs). Instead of having to invest in many different stocks to achieve diversification, investors can invest in a single or a few ETFs and instantly be invested in hundreds or thousands of companies.
Neutral
Zacks Investment Research
2 days ago
Should You Invest in the Vanguard Information Technology ETF (VGT)?
The Vanguard Information Technology ETF (VGT) was launched on 01/26/2004, and is a passively managed exchange traded fund designed to offer broad exposure to the Technology - Broad segment of the equity market.
Negative
The Motley Fool
6 days ago
1 Artificial Intelligence (AI) ETF to Buy Hand Over Fist and 1 to Avoid
It looks like artificial intelligence (AI) is more than the latest fad. The technology is becoming an integral part of how people do things, from work to play, offering solutions to simplify complex activities.
Positive
Zacks Investment Research
1 week ago
Big ETF Inflows of Last Week: QQQ, IBIT & More
QQQ and IBIT led last week's $17B ETF inflows, as investors piled into tech, Bitcoin, and gold amid market resilience.
Positive
The Motley Fool
2 weeks ago
2 Unstoppable Vanguard ETFs That Have Doubled in Just 5 Years
Investing in exchange-traded funds (ETFs) is usually associated with safe and stable long-term investing. But not all ETFs are the same.
Neutral
The Motley Fool
2 weeks ago
1 Magnificent Vanguard ETF to Confidently Buy With $600 During the Stock Market Rebound
The S&P 500 was down by as much as 19% from its all-time high after President Trump announced his "Liberation Day" tariffs on April 2. But it erased those losses since then because several countries have come to the table to negotiate new trade deals and the federal Court of International Trade ruled many of the tariffs were illegal, lowering the odds of an economic downturn.
Positive
The Motley Fool
2 weeks ago
3 Unstoppable Vanguard ETFs I'm Buying and Holding Forever -- Even if a Recession Is Coming
If the recent stock market rollercoaster has you feeling nauseated, you're not alone. Investor sentiment has been swinging wildly in recent months, with 43% of investors feeling optimistic about the market in January to only 19% in March to around 38% most recently, according to weekly surveys from the American Association of Individual Investors.
Positive
The Motley Fool
2 weeks ago
4 Vanguard ETFs to Buy With $500 and Hold Forever
Whether you're new to investing or have years of experience, buying exchange-traded funds (ETFs) can be a smart way to build your portfolio. They offer instant diversification and can even give you targeted exposure to specific sectors.
Neutral
Business Wire
3 weeks ago
Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor targeted imaging agents, announced new data being presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results demonstrate that using intraoperative molecular imaging (IMI) with abenacianine for injection (VGT-309), the company's investigational tumor-targeted fluorescent imaging agent, during lung surgery has the potential to help optimize tumor resectio.
Neutral
Seeking Alpha
3 weeks ago
VGT Vs. QQQ: Which Is The Best Growth ETF?
VGT offers slightly lower fees and broader tech sector exposure, but is more top-heavy and excludes major tech names like Amazon, Google, and Meta. QQQ provides access to the full Magnificent 7, is less top-heavy, and includes non-tech growth leaders, but at a slightly higher expense ratio. VGT has outperformed QQQ over the past decade, but its long-term performance since inception has been below that of QQQ.
Charts implemented using Lightweight Charts™